Key result
Platelet hyperaggregation linked to ~13-fold higher cardiovascular event risk in CAD, driven by CYP2C19 polymorphisms.
Why the study?
Does CYP2C19 polymorphism increase the risk of cardiovascular events in Indonesian patients with stable CAD treated with clopidogrel?
Cohort (n=69)
Yes
Does CYP2C19 polymorphism increase the risk of cardiovascular events in Indonesian patients with stable CAD treated with clopidogrel?
In Indonesian patients with stable CAD on clopidogrel, CYP2C19 variant alleles are associated with platelet hyperaggregation and an increased risk of cardiovascular events.
Answers are grounded in this paper and cite their sources.
May warrant caution with standard clopidogrel dosing in Indonesian CYP2C19 carriers; leaves open need for genotype-guided trials before practice change.
Background: The polymorphism of cytochrome P450 2C19 (CYP2C19) has been documented as the determinant variability in the antiplatelet effect of clopidogrel. The relation between CYP2C19 polymorphism and the antiplatelet efficacy of clopidogrel in Indonesian patients with coronary artery disease (CAD) is unknown. To address this issue, we examined the distribution of CYP2C19 genotypes and platelet aggregation, and assessed the impact of CYP2C19 polymorphism on response to clopidogrel and cardiovascular events. Methods: This observational analytic study with prospective cohort approach was conducted in Wahidin Sudirohusodo and Hasanuddin University Hospital, Makassar. We measured the CYP2C19 genotype by polymerase chain reaction-restriction fragment linked polymorphism (PCR-RFLP) method and platelet aggregation by optical platelet aggregometry with 10 μmol of adenosine diphosphate (ADP) in 69 patients with stable CAD who were treated with clopidogrel. Platelet hyperaggregation was defined as maximal platelet aggregation > 94.3%. The patients were followed up every month at the outpatient department for 6 months or at end point. The end point was acute myocardial infarction, ischemic stroke, or cardiovascular death. Results: Distribution of CYP2C19 alleles were 89.8%, 40.6%, and 11.6%, in CYP2C19*1, CYP2C19*2, and CYP2C19*3, respectively. Distribution of CYP2C19 genotype were 50.7%, 29.0%, 8.7%, 8.7%, and 2.9% in CYP2C19*1/*1, *1/*2, *1/*3, *2/*2, and *2/*3, respectively. Platelet hyper aggregation was more in patients with polymorphism than wild type (p 0.034; OR 3.707) and was associated with cardiovascular events (p 0.030; OR 13.250). There was acute myocardial infarction in 2 patients, ischemic stroke in 1 patient, and cardiovascular death in 1 patient. All of these patients were carrying at least one variant allele of CYP2C19; details of genotype were in two patients with CYP2C19*1/*2, one patient with *2/*2, and one with *2/*3 alleles. Conclusion: CYP2C19*2 and *3 were associated with cardiovascular events due to platelet hyper aggregation.
No takes yet. Share an insight, caveat, or question.
Amir et al. (2017) conducted a cohort in Coronary Artery Disease (n=69). CYP2C19 polymorphism (*2 or *3 variant alleles) vs. CYP2C19 wild type (*1/*1) was evaluated on Cardiovascular events (acute myocardial infarction, ischemic stroke, or cardiovascular death) (OR 13.250, p=0.030). Platelet hyperaggregation, which was more common in patients with CYP2C19 polymorphisms, was associated with a increased risk of cardiovascular events in Indonesian patients with coronary artery disease.
Synapse has enriched 10 related papers. Consider them for comparative context: